Wall Street Zen Upgrades CalciMedica (NASDAQ:CALC) to Sell

CalciMedica (NASDAQ:CALC) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $16.00.

CalciMedica Trading Down 2.8%

NASDAQ:CALC opened at $5.13 on Friday. The company has a quick ratio of 4.04, a current ratio of 4.03 and a debt-to-equity ratio of 1.39. CalciMedica has a 1-year low of $1.42 and a 1-year high of $7.20. The firm has a market capitalization of $73.92 million, a price-to-earnings ratio of -3.17 and a beta of 0.49. The stock has a fifty day simple moving average of $4.84 and a 200 day simple moving average of $3.62.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. Sell-side analysts forecast that CalciMedica will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of CalciMedica during the 3rd quarter valued at $165,000. Sheets Smith Investment Management purchased a new stake in shares of CalciMedica during the third quarter worth $157,000. Envestnet Asset Management Inc. raised its holdings in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares in the last quarter. 180 Wealth Advisors LLC boosted its position in CalciMedica by 207.6% during the second quarter. 180 Wealth Advisors LLC now owns 50,450 shares of the company’s stock valued at $81,000 after purchasing an additional 34,050 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC purchased a new position in CalciMedica in the second quarter valued at about $32,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.